Studies of exercise in people
1,238 studies gave exercise to people and measured what changed
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases FGF23 | Trial24 h | 10 peopleWomenpremenopausalFollowing resistance or interval-running exercise | Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme, Nov 16, 2026 |
no change: Has no effect on food-related ERP responsesInteraction adjusted p: N2 = 0.1635; P3 = 0.5248; LPP = 0.5248 no change: Has no effect on behavioral accuracyAccuracy p = 0.7978; reaction time p = 0.7221 | Randomized trialacute | 17 peopleadultsOverweight or obesity; food-related Flanker task | Life (Basel, Switzerland), Nov 14, 2026 |
down: Decreases fatigue5.1-point reduction in PROMIS Fatigue 7a T-score (95% CI 3.6–6.7) up: Improves relative peak aerobic capacity+3.1 ml/kg/min (95% CI 2.1–4.0) | Trial12 weeks | 72 peopleAdvanced prostate cancer receiving ADT-based therapy | The oncologist, Nov 12, 2026 |
no change: Has no effect on peak oxygen uptakeBaseline-adjusted difference 1.15 mL/kg/min; 95% CI −0.66 to 2.96; P=0.204 no change: Has no effect on serious exercise-related adverse eventsNo serious exercise-related adverse events reported | Randomized trial12 weeks | 30 peopleClinically stable chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty | Frontiers in cardiovascular medicine, Nov 10, 2026 |
| Trial1.5 hours | 20 people27.3±1.2 yearsMidlife adults; Endurance-trained athletes under fed and/or fasted conditions | The Journal of clinical endocrinology and metabolism, Nov 7, 2026 | |
down: Decreases painMean difference −1.24, 95% CI −1.59 to −0.89 up: Increases 6-minute walk distanceMean difference 38.94 m, 95% CI 29.59 to 48.28 down: Decreases depressionBDS mean difference −4.52, 95% CI −6.51 to −2.54 | Randomized trial12 weeks | 48 peopleOsteoporotic vertebral fractures | Physiotherapy research international : the journal for researchers and clinicians in physical therapy, Nov 7, 2026 |
down: Decreases CESD-R-20 scoreMean 13.97 to 12.33 points; median 14 to 10 points; scores decreased in 39 participants (59.1%) | Trial | 66 peopleolder adultsOlder adults; uncontrolled, single-group pre- and post-intervention comparison | Revista Multidisciplinar do Nordeste Mineiro, Nov 4, 2026 |
down: Decreases blood glucose no change: Has no effect on daily mean glycemic exposure up: Increases within-day glycemic variability | Randomized trial8-day protocol | 29 peopleadultsGeneral population; evening exercise (16:00-19:00) compared with morning exercise (07:00-10:00); normal glucose tolerance | bioRxiv, Nov 2, 2026 |
down: Decreases systolic blood pressureMedian systolic blood pressure: 156.50 to 141.50 mmHg; median diastolic blood pressure: 91.00 to 85.50 mmHg | Trial | 26 peopleolder adultsOlder adults; hypertension; one-group pretest–posttest comparison without a control group | Healthy Journal, Oct 31, 2026 |
up: Improves functional mobility down: Decreases depressive symptoms up: Improves quality of life | Randomized trialeight weeks | 40 people60 years and overOlder adults; in older adults with sarcopenia | Geriatric nursing (New York, N.Y.), Oct 31, 2026 |
up: Improves peak VO2interaction estimate per 10-point increase: 7.30%; 95% CI 0.66–13.94; p=0.032 | Randomized trial24 weeks | 91 peopleBothmedian age 63 years, IQR 57–71Older adults; Midlife adults; modified by baseline healthcare health literacy | ESC Congress 2026 abstract, Oct 26, 2026 |
no change: Has no effect on coronary microvascular function up: Increases flow-mediated vasodilation | Randomized trial12 months | 21 peoplePrevious myocardial infarction; intervention and control groups merged for baseline-to-follow-up analysis | ESC Congress 2026 abstract, Oct 26, 2026 |
up: Improves grip strength+3.1 kg from baseline; 28.9→32.0 kg down: Decreases frailtyFrailty score −0.40 from baseline; 1.63→1.23 up: Improves cognitive functionK-MMSE +0.81 from baseline; 27.98→28.79 | Randomized trial6 months | 100 peopleChronic heart failure | ESC Congress 2026 abstract, Oct 26, 2026 |
no change: Has no effect on fasting glucose no change: Has no effect on inflammatory markers | Randomized trial24-36 weeks of gestation | 263 peopleWomenPregnancy with obesity | medRxiv, Oct 24, 2026 |
up: Improves functional capacity+33 to +73 m in all participants up: Increases grip strengthRight hand: +0.5 to +5.5 kg in all patients; left hand: +2.0 to +3.5 kg in three patients up: Improves quality of lifeSeveral domains improved in most participants | Treated cohort12 weeks | 5 peopleWomenEstablished cancer cachexia; uncontrolled baseline-to-post-intervention comparison | Healthcare (Basel, Switzerland), Oct 23, 2026 |
up: Improves short Physical Performance Battery scoremean between-group difference of − 2.74 points (95% CI − 4.21 to − 1.27), Cohen's d = 0.68 no change: Has no effect on time to first bowel movement no change: Has no effect on postoperative complications | Randomized trialpostoperative days 1, 3, and 5 | 31 peoplePatients undergoing elective colorectal surgery | Perioperative medicine (London, England), Oct 16, 2026 |
up: Improves chemotherapy-induced peripheral neuropathy symptomsp < 0.001 | Trial10-week | 36 peopleBothmedian age: 59Cancer survivors experiencing CIPN symptoms ≥6 months post-chemotherapy | Current oncology (Toronto, Ont.), Oct 15, 2026 |
up: Improves cognitive functionGood cognitive function: 0% pretest versus 70% posttest; reported scores 4.608±0.499 pretest versus 4.260±0.499 posttest | Trial | 50 peopleolder adultsOlder adults; uncontrolled pretest–posttest comparison | International Journal of Drug Delivery Technology, Oct 15, 2026 |
up: Improves muscle strength+11.7% up: Improves functional performance+8.3% down: Decreases anxiety | Trial14 weeks | 16 people16 women51.31 ± 9.17 years, range 31 to 66Patient cohorts | Research Square, Oct 14, 2026 |
no change: Has no effect on intrahepatic fat fraction−0.8 percentage points versus usual care; 95% CI −2.4 to 0.8; P = 0.54 | Randomized trial12 weeks | 187 peopleBothadultsObesity | Nature communications, Oct 14, 2026 |
no change: Has no effect on muscle fiber size no change: Has no effect on skeletal muscle fibrosis down: Decreases fibro-adipogenic progenitor abundance | Randomized trial12 weeks | 19 peopleStage 3-5 chronic kidney disease | American journal of physiology. Renal physiology, Oct 7, 2026 |
down: Decreases brachial-ankle pulse wave velocity up: Increases flow-mediated dilation down: Decreases heart rate variability | Randomized trial | 17 peopleMenMen with elevated BP | Clinical physiology and functional imaging, Oct 5, 2026 |
| Randomized trial12 weeks | 48 peopleprimarily male (92%)67.5 years old (SD = 3.6)Older veterans with PTSD | Mental health and physical activity, Oct 1, 2026 | |
down: Decreases systolic blood pressure142.00 ± 18.13 to 132.33 ± 19.96 mmHg, P=0.007 no change: Has no effect on timed Up and Go test6.05 ± 1.00 to 5.84 ± 0.81 seconds, P=0.066 no change: Has no effect on grip strength | Trialaverage period of 10.0 ± 4.1 months | 9 peoplemean age of 68.1 ± 6.7 yearsCommunity-dwelling older adults | Journal of rural medicine : JRM, Oct 1, 2026 |
| Trialmedian 5.5 days (IQR, 1.5–11.75) | 26 people57.7% were malemedian age 52.5 years (IQR, 43.3–62.8)Adult inpatients admitted to general wards with at least 48 hours of hospitalization, clinically stable, functionally independent, and without prior physiotherapy referral | Physiotherapy research international : the journal for researchers and clinicians in physical therapy, Oct 1, 2026 | |
down: Decreases frailty43.5% classified as nonfrail after intervention | Trial12 weeks | 46 peopleBoth68.83 yearsOlder adults; initially frail or prefrail older adults | Archivos en Medicina Familiar, Oct 1, 2026 |
up: Improves balance | Trial12 weeks | 60 people55–65 yearsMidlife adults; Older adults | Sport Mont, Oct 1, 2026 |
up: Improves 30-second chair stand test performance17.9±3.5 to 23.7±4.5 reps (control), 18.3±4.0 to 26.6±4.8 reps (experimental) up: Improves timed Up and Go performance5.6±0.9 to 4.8±0.8 s (control), 5.6±0.8 to 5.0±0.5 s (experimental) | Trial8-week | 26 peopleWomen66.8±4.8 yearsOlder adults | Sport Mont, Oct 1, 2026 |
down: Lowers the risk of postoperative complications18% vs 48%, OR 0.34 (95% CI 0.13-0.92) up: Improves exercise tolerance down: Decreases NT-proBNP | Randomized trial14-18 days | 80 peopleIn frail patients undergoing coronary artery bypass grafting | Bulletin of Siberian Medicine, Oct 1, 2026 |
up: Improves EQ-5D indexmean paired difference = 0.07 up: Improves sit-to-stand performancemean paired difference = 2.98 up: Increases average daily step countmean paired difference = 638 | TrialMedian duration of participation in TEC was 9 months | 168 peoplemenmean (SD) age of 70.6 years (7.8)Patients receiving treatment for prostate cancer | BJUI compass, Sep 30, 2026 |
| Randomized trial | 310 peopleBothaverage age 87 yearsThe oldest old; Older adults; during acute hospitalization | European geriatric medicine, Sep 30, 2026 | |
no change: Has no effect on processing speed up: Increases moderate to vigorous physical activityb = 4.33 minutes/day, P <.01 up: Improves attentionb = 0.14, P = 0.03 | Randomized trial6-month physical activity intervention, with 6 months of maintenance support | 253 peoplefemaleaverage 58.5 years old, ranging from 40 to 82 years oldFemale breast cancer survivors | Journal of the National Cancer Institute, Sep 30, 2026 |
down: Decreases GrimAge2 down: Decreases DNAmFitAge | Randomized trial12-month | 124 peopleWomenon average 58.8 years oldSedentary breast cancer survivors within 5 years of diagnosis | Journal of the National Cancer Institute, Sep 30, 2026 |
up: Increases 2-Minute Walk Test distanceT2 versus T1: 5.00 m (95% CI: -0.29 to 10.29); mixed-model p = 0.063; paired comparison p = 0.046 no change: Has no effect on exercise-testing outcomesNumerical increases were not statistically significant | Trial12 weeks | 20 peopleadultsMultiple sclerosis; uncontrolled within-group comparison | Life (Basel, Switzerland), Sep 29, 2026 |
down: Decreases systolic blood pressure-4.6 mmHg (95% CI: 2.36-6.84) down: Decreases diastolic blood pressure-2.4 mmHg (95% CI: 0.53-3.27) down: Decreases perceived stress-2.5 points (95% CI: 1.87-4.67) | Randomized trial12 weeks | 27 peopleGeneral population | Acta psychologica, Sep 29, 2026 |
| Randomized trial12 weeks | 24 peopleBothmean age 53Patient cohorts; Midlife adults | Topics in spinal cord injury rehabilitation, Sep 28, 2026 | |
up: Increases peak oxygen consumptionB = 2.12 up: Increases anaerobic thresholdB = 1.83 up: Improves gait speedB = 0.07 | Randomized trial12 weeks | 120 people20–80 yearsParticipants aged 20–80 years with long COVID | Research Square, Sep 25, 2026 |
up: Improves freezing of gait questionnaireSMD -0.62, 95% CI -1.06 to -0.18 up: Improves Unified Parkinson's Disease Rating Scale Part IIISMD -0.80, 95% CI -1.02 to -0.59 up: Improves berg Balance ScaleSMD 0.85, 95% CI 0.27 to 1.42 | Review of trials | 714 people pooledPatients with PD | PloS one, Sep 25, 2026 |
up: Increases CD8+ TEMRA cellsHedges’ g = 1.26 down: Decreases CD8+ naive T cellsHedges’ g = − 1.16 down: Prevents insulin | Trial12-week | 11 peoplewomen49.1 ± 14.4 yearsPatients with histologically confirmed breast cancer undergoing (neo)adjuvant chemotherapy (± immunotherapy) | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, Sep 24, 2026 |
down: Decreases being told they had poor memoryOR 0.61, 95% CI 0.38 to 0.98 up: Improves ability to shop for food or other necessitiesOR 1.53, 95% CI 1.07 to 2.20 no change: Has no effect on proportion of daily activities performedOR 0.96, 95% CI 0.69 to 1.33 | Randomized trialapproximately 2 weeks before surgery and continuing for 4 weeks after discharge | 761 people39% were womenmedian age of 70 yearsPatients aged 20 years or older with colorectal cancer scheduled to undergo elective surgery with curative intent | BMJ open, Sep 23, 2026 |